HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Akorn’s Zatidor generic

This article was originally published in The Tan Sheet

Executive Summary

FDA grants Akorn approval July 27 for its generic version of Novartis' Zatidor OTC ophthalmic solution (ketotifen fumarate 0.025%), the Buffalo Grove, Ill.-based firm announces in a same-day release. The product, which was approved for OTC use by the agency in October 2006, is indicated for up to 12 hours of relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander, Akorn states (1"The Tan Sheet" Oct. 23, 2006, p. 4). The firm estimates Novartis' branded product posted $36 mil. in sales in 2006. The firm plans to launch the product by October, according to the release. Bausch & Lomb has already announced the release of its Zatidor equivalent (2"The Tan Sheet" July 2, 2007, In Brief)...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts